FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171883873> ?p ?o ?g. }

• W2171883873 endingPage "1057" @default.
• W2171883873 startingPage "1050" @default.
• W2171883873 abstract "Purpose This is a randomized, double-blind, placebo-controlled study aimed to evaluate the clinical and biologic effects of letrozole plus lapatinib or placebo as neoadjuvant therapy in hormone receptor (HR) –positive/human epidermal growth factor receptor 2 (HER2) –negative operable breast cancer. Methods Ninety-two postmenopausal women with stage II to IIIA primary breast cancer were randomly assigned to preoperative therapy consisting of 6 months of letrozole 2.5 mg orally daily plus lapatinib 1,500 mg orally daily or placebo. Surgery was performed within 2 weeks from the last study medication. Clinical response was assessed by ultrasonography. Pre- and post-treatment samples were evaluated for selected biomarkers. Fresh-frozen tissue samples were collected for genomic analyses. Results Numerically similar clinical response rates (partial + complete response) were observed (70% for letrozole-lapatinib and 63% for letrozole-placebo). Toxicities were generally mild and manageable. A significant decrease in Ki-67 and pAKT expression from baseline to surgery was observed in both arms. Overall, 34 patients (37%) had a mutation in PIK3CA exon 9 or 20. In the letrozole-lapatinib arm, the probability of achieving a clinical response was significantly higher in the presence of PIK3CA mutation (objective response rate, 93% v 63% in PIK3CA wild type; P = .040). Conclusion The combination of letrozole-lapatinib in early breast cancer was feasible, with expected and manageable toxicities. In unselected estrogen receptor–positive/HER2-negative patients, letrozole-lapatinib and letrozole-placebo resulted in a similar overall clinical response rate and similar effect on Ki-67 and pAKT. Our secondary end point findings of a significant correlation between PIK3CA mutation and response to letrozole-lapatinib in HR-positive/HER2-negative early breast cancer must now be independently confirmed." @default.
• W2171883873 created "2016-06-24" @default.
• W2171883873 creator A5004433815 @default.
• W2171883873 creator A5004984896 @default.
• W2171883873 creator A5005011926 @default.
• W2171883873 creator A5008274065 @default.
• W2171883873 creator A5015790566 @default.
• W2171883873 creator A5018395267 @default.
• W2171883873 creator A5020078965 @default.
• W2171883873 creator A5022648629 @default.
• W2171883873 creator A5028688292 @default.
• W2171883873 creator A5033216433 @default.
• W2171883873 creator A5034632931 @default.
• W2171883873 creator A5034987953 @default.
• W2171883873 creator A5038784620 @default.
• W2171883873 creator A5048969389 @default.
• W2171883873 creator A5050279204 @default.
• W2171883873 creator A5068497911 @default.
• W2171883873 creator A5070082971 @default.
• W2171883873 creator A5074749942 @default.
• W2171883873 creator A5075817712 @default.
• W2171883873 creator A5077942090 @default.
• W2171883873 date "2014-04-01" @default.
• W2171883873 modified "2023-10-06" @default.
• W2171883873 title "Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Operable Breast Cancer" @default.
• W2171883873 cites W155933052 @default.
• W2171883873 cites W1985453548 @default.
• W2171883873 cites W2014001512 @default.
• W2171883873 cites W2022102157 @default.
• W2171883873 cites W2029882446 @default.
• W2171883873 cites W2031675384 @default.
• W2171883873 cites W2048131754 @default.
• W2171883873 cites W2058085109 @default.
• W2171883873 cites W2058585724 @default.
• W2171883873 cites W2062071674 @default.
• W2171883873 cites W2090561517 @default.
• W2171883873 cites W2097698108 @default.
• W2171883873 cites W2104919541 @default.
• W2171883873 cites W2109189228 @default.
• W2171883873 cites W2109439031 @default.
• W2171883873 cites W2109462843 @default.
• W2171883873 cites W2110444464 @default.
• W2171883873 cites W2111253826 @default.
• W2171883873 cites W2113435829 @default.
• W2171883873 cites W2117873881 @default.
• W2171883873 cites W2125239609 @default.
• W2171883873 cites W2128995479 @default.
• W2171883873 cites W2136034662 @default.
• W2171883873 cites W2153061474 @default.
• W2171883873 cites W2154142993 @default.
• W2171883873 cites W2154488022 @default.
• W2171883873 cites W2161433585 @default.
• W2171883873 cites W2165037690 @default.
• W2171883873 doi "https://doi.org/10.1200/jco.2013.51.4737" @default.
• W2171883873 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24590635" @default.
• W2171883873 hasPublicationYear "2014" @default.
• W2171883873 type Work @default.
• W2171883873 sameAs 2171883873 @default.
• W2171883873 citedByCount "44" @default.
• W2171883873 countsByYear W21718838732014 @default.
• W2171883873 countsByYear W21718838732015 @default.
• W2171883873 countsByYear W21718838732016 @default.
• W2171883873 countsByYear W21718838732017 @default.
• W2171883873 countsByYear W21718838732018 @default.
• W2171883873 countsByYear W21718838732019 @default.
• W2171883873 countsByYear W21718838732020 @default.
• W2171883873 countsByYear W21718838732021 @default.
• W2171883873 countsByYear W21718838732022 @default.
• W2171883873 countsByYear W21718838732023 @default.
• W2171883873 crossrefType "journal-article" @default.
• W2171883873 hasAuthorship W2171883873A5004433815 @default.
• W2171883873 hasAuthorship W2171883873A5004984896 @default.
• W2171883873 hasAuthorship W2171883873A5005011926 @default.
• W2171883873 hasAuthorship W2171883873A5008274065 @default.
• W2171883873 hasAuthorship W2171883873A5015790566 @default.
• W2171883873 hasAuthorship W2171883873A5018395267 @default.
• W2171883873 hasAuthorship W2171883873A5020078965 @default.
• W2171883873 hasAuthorship W2171883873A5022648629 @default.
• W2171883873 hasAuthorship W2171883873A5028688292 @default.
• W2171883873 hasAuthorship W2171883873A5033216433 @default.
• W2171883873 hasAuthorship W2171883873A5034632931 @default.
• W2171883873 hasAuthorship W2171883873A5034987953 @default.
• W2171883873 hasAuthorship W2171883873A5038784620 @default.
• W2171883873 hasAuthorship W2171883873A5048969389 @default.
• W2171883873 hasAuthorship W2171883873A5050279204 @default.
• W2171883873 hasAuthorship W2171883873A5068497911 @default.
• W2171883873 hasAuthorship W2171883873A5070082971 @default.
• W2171883873 hasAuthorship W2171883873A5074749942 @default.
• W2171883873 hasAuthorship W2171883873A5075817712 @default.
• W2171883873 hasAuthorship W2171883873A5077942090 @default.
• W2171883873 hasBestOaLocation W21718838731 @default.
• W2171883873 hasConcept C121608353 @default.
• W2171883873 hasConcept C126322002 @default.
• W2171883873 hasConcept C142724271 @default.
• W2171883873 hasConcept C143998085 @default.
• W2171883873 hasConcept C204787440 @default.
• W2171883873 hasConcept C27081682 @default.
• W2171883873 hasConcept C2777176818 @default.

• next